Long-term control of metastatic urothelial carcinoma resistant to platinum-based therapy: clinical case
DOI: 10.32364/2587-6821-2023-7-6-1
A.S. Shatokhina
Clinical Oncological Dispensary No 1, Krasnodar, Russian Federation
Urothelial carcinoma is the most commonly diagnosed malignant tumor of the bladder and/or upper urinary tract. Besides, bladder cancer is a socially significant disease that occupies the 9th place in the oncopathology structure, in which middle-aged and older men mainly become ill. Anticancer therapy of patients with metastatic urothelial cancer in the first line is currently well studied and has its own standards that are actively used in clinical practice. However, the problem of choosing anticancer therapy for patients with metastatic urothelial cancer in the second line is still relevant. Vinflunine therapy is a possible option for the treatment of such patients. The presented clinical case demonstrated long-term control of metastatic urothelial carcinoma in a 67-year-old male patient resistant to platinum-based therapy. The patient received 24 cycles of vinflunine therapy. Hematological toxicity in the form of anemia and grade 1 neutropenia and non-hematological toxicity — grade 2 asthenia, grade 1 myalgia, grade 2 bone pain, which did not require dose reduction or therapy discontinuation, were noted during treatment with vinflunine. Vinflunine therapy provided stabilization of the oncological process and a decrease in the pain syndrome severity, which allowed to refuse taking analgesics.
Keywords: metastatic urothelial carcinoma, bladder cancer, inefficacy of platinum-based chemotherapy, second-line therapy, vinflunine, efficacy, safety, life quality.
For citation: Shatokhina A.S. Long-term control of metastatic urothelial carcinoma resistant to platinum-based therapy: clinical case. Russian Medical Inquiry. 2023;7(6):391–395 (in Russ.). DOI: 10.32364/2587-6821-2023-7-6-1.
About the author:
Alina S. Shatokhina — oncologist, Head of the Department of Anticancer Drug Therapy and Chemotherapy, Clinical Oncological Dispensary No 1; 146, Dimitrova str., Krasnodar, 350040, Russian Federation; ORCID iD 0000-0001-7719-370X. Contact information: Alina S. Shatokhina, e-mail: alina.shatokhina@yandex.ru.
Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 04.04.2023.
Revised 27.04.2023.
Accepted 22.05.2023.
2. American Cancer Society. Cancer Facts & Figures 2023. Atlanta, Ga: American Cancer Society; 2023.
3. Bellmunt J., Fougeray R., Rosenberg J.E. et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–1472. DOI: 10.1093/annonc/mdt007.
4. Гладков О.А., Матвеев В.Б., Митин Т. (США) и др. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли: Практические рекомендации RUSSCO. 2017;7(3s2):411–420. [Gladkov O.A., Matveev V.B., Mitin T. (USA) et al. Practical recommendations for the medicinal treatment of bladder cancer. Malignant tumors: Practical recommendations RUSSCO. 2017;7(3s2):411–420 (in Russ.)].
5. Жабина А.С., Новиков А.И., Моисеенко Ф.В. и др. Рак мочевого пузыря. Ретроспективный анализ использования винфлунина в реальной клинической практике. Research'n Practical Medicine Journal. 2021;8(2):34–42. DOI: 10.17709/2410-1893-2021-8-2-3. [Zhabina A.S., Novikov A.I., Moiseenko F.V. et al. Bladder cancer. A retrospective analysis of the use of vinfluvin in real clinical practice. Research and Practical Medicine Journal (Issled. prakt. med.). 2021;8(2):34–42 (in Russ.)]. DOI: 10.17709/2410-1893-2021-8-2-3.
6. Bamias A., Hegele A., Medioni J. et al. Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and metaanalysis of real-world series. Crit Rev Oncol Hematol. 2019;140:80–87. DOI: 10.1016/j.critrevonc.2019.05.006.
7. Kapetanakis V., Prawitz T., Schlichting M. et al. Comparing progressionfree survival (PFS) in second-line (2L) urothelial carcinoma (UC) treatments from single-arm trials: Importance of using appropriate methods. J Clin Oncol. 2020;38(Suppl 6):573. DOI: 10.1200/JCO.2020.38.6_suppl.573.
8. Baldini C., Champiat S., Vuagnat P., Massard C. Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. Onco Targets Ther. 2019;12:2505–2512. DOI: 10.2147/OTT.S141040.
9. Teo M.Y., Seier K., Ostrovnaya I. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–1694. DOI: 10.1200/JCO.2017.75.7740.
11. Болотина Л.В., Заборский И.Н., Сафиуллин К.Н. и др. Рак мочевого пузыря: лечение после прогрессирования. Результаты 2-го ретроспективного анализа данных по применению винфлунина у пациентов с метастатическим уротелиальным раком в условиях реальной клинической практики в России. Онкоурология. 2020;16(3):135–142. DOI: 10.17650/1726-9776-2020-16-3-135-142. [Bolotina L.V., Zaborskiy I.N., Safiullin K.N. et al. Bladder cancer: treatment after progression. Results ofthe second retrospective analysis of data on the efficacy of vinflunin in patients with metastatic urothelial cancer in real clinical practice in Russia. Onko-urologiya=Cancer Urology 2020;16(3):135–142 (in Russ.)]. DOI: 10.17650/1726-9776-2020-16-3-135-142.
12. Riedel F., Munker M., Roghmann F. et al. Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis. Cancers (Basel). 2022;14(12):2850. DOI: 10.3390/cancers14122850.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
